Ainuovirine vs CL-197

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Ainuovirine

Marketed by Jiangsu Aidea Pharmaceutical Group under a licence from Kainos Medicine

Phase 1 in HIVsmall molecule
Weak signal

NCT01348516 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Safety/ Tolerability Evaluation". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: June 2028 · NCT07631897 (registry estimate)

Reported efficacy

Safety/ Tolerability Evaluation (participants will be followed for the duration of hospital stay, 8-10 days for SAD and 14-16 days for MAD): In 80 healthy male volunteers given single or multiple doses (once daily for 7 days) of 75, 150, 300 or 600 mg or placebo, the drug was generally well tolerated with no serious adverse events and showed dose- and time-dependent nonlinear pharmacokinetics across the 75 to 600 mg range.

Result source: NCT01348516

CL-197

Developed by Henan Genuine Biotech

Phase 2 in HIVsmall molecule
Weak signal

NCT05944848 · Phase 1 · completed

The study randomly assigned healthy volunteers to active drug or matching placebo and blinded participants, care providers, investigators, and outcome assessors, which are the hallmarks of a well-controlled study. However, it tested only safety and drug levels in healthy volunteers rather than any HIV outcome, and results have not been posted. Its registered primary outcome on ClinicalTrials.gov is "The Safety and Tolerability of CL-197 Capsules :Incidence of Treatment-Emergent Adverse Events as Assessed by The NCI CTCAE V5.0 Grading Criteria". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2026 · NCT07308782 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAinuovirineCL-197
HIV-1 RNA below 50 copies/mL (week 48)—Not reported—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Not reported—Not reported
CD4 count, change (week 48)—Not reported—Not reported

HIV-1 RNA below 50 copies/mL (week 48)

Ainuovirine
—Not reported
CL-197
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

Ainuovirine
—Not reported
CL-197
—Not reported

CD4 count, change (week 48)

Ainuovirine
—Not reported
CL-197
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Ainuovirine: no structured comparison results are available for HIV.

CL-197: no structured comparison results are available for HIV.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ainuovirine's landscape · CL-197's landscape